SAN DIEGO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 12 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc. , a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave(R) (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products. The financial terms of the deal were not disclosed.
“We have crafted a strategic, long-term partnership predicated on a shared commitment to maximizing the potential of Contrave and Empatic and to the mission of addressing the significant health issue of obesity,” said Wes Wheeler, President and CEO of Patheon.
About Patheon
Patheon Inc. is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to approximately 300 of the world’s leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, multi-layer tablets, pre-filled syringes and a variety of modified release technologies.
Patheon, with an integrated development and manufacturing network of 11 facilities and eight development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.
CONTACT: Graham Cooper, Chief Financial Officer of Orexigen Therapeutics,
Inc., +1-858-875-8600; or Liz Frank of WCG, +1-212-301-7216, for Orexigen
Therapeutics, Inc.; or Wes Wheeler, President and Chief Executive Officer,
+1-919-226-3200, wes.wheeler@patheon.com, or Eric Evans, Chief Financial
Officer, +1-919-226-3204, eric.evans@patheon.com, or Wendy Wilson, Investor
Relations, +1-919-226-3313, wendy.wilson@patheon.com, all of Patheon Inc.
Web site: http://www.Orexigen.com/
